$ENDP $190M deal: Endo buying North Jersey specialty pharma

New Post Public Reply Private Reply Replies (0) Message Board
jonny_red32
684
$ENDP $190M deal: Endo buying North Jersey specialty pharma company



Endo International reached a definitive agreement to acquire Somerset Therapeutics and its affiliated contract manufacturer in India for $190 million.

Based in Somerset, N.J., Somerset Therapeutics is a specialty pharmaceutical company that develops and markets sterile injectable products. Its Bangalore, India, affiliate, Wintac Ltd., operates as Somerset Therapeutics' contract developer and manufacturer.

Paul Campanelli, president and CEO of Endo, said the acquisition will expand the product portfolio of its Par Sterile Products business Endo acquired when it\s paid $8 billion to buy Par Pharmaceutical of Woodcliff Lake, N.J., in 2015.

"Additionally," Campanelli said, "Wintac's strong sterile R&D and high-quality manufacturing capabilities have contributed greatly to Somerset Therapeutics' steady revenue growth. We see significant opportunities to leverage our existing sales and marketing capabilities as we seek to maximize the value of the current and expected future Somerset Therapeutics' products."

Somerset Therapeutics' portfolio includes eight commercial products as well as a pipeline of more than 40 others – more than 25 of which have been submitted for approval by the Food and Drug Administration.

"Par has deep experience in the growing U.S. sterile injectable drugs market," said Dr. Veerappan Subramanian, chairman and CEO of Somerset Therapeutics, in a statement. "They are well-suited to move Somerset Therapeutics and Wintac's business to the next stage of development and growth."

The deal, which requires regulatory approvals in the United States and India, is expected to close by the end of the year. After the deal is finalized, Somerset Therapeutics will become a wholly owned subsidiary of Par Pharmaceutical and the Wintac business will become part of Par Formulations Private Ltd.

K&L Gates and Shardul Amarchand Mangaldas & Co. are acting as Endo's legal counsel for the transaction.

Endo International plc (ENDPQ) Stock Research Links

ENDPQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment






Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

8x8, Inc. Achieves Earnings Beat with Strong Future Guidance

Updated Category News Views 91

8x8, Inc. Reports Strong Earnings Amid Growth Initiatives 8x8, Inc. (NASDAQ: EGHT), the prominent cloud communications provider, has experienced a notable uptick of 2% in its share value during after-hours trading following the release of their latest quarterly earnings. The company reported second quarter results that exceeded market expectations, providing a boost in...

Continue Reading
Investors Can Take Action in Indivior PLC Fraud Case Today

Updated Category News Views 73

Investors Encouraged to Join Indivior PLC Securities Fraud Lawsuit The Schall Law Firm, a well-known litigation firm dedicated to protecting shareholders' rights, is reaching out to investors about an important class action lawsuit against Indivior PLC (NASDAQ: INDV). This case concerns potential breaches of the Securities Exchange Act of 1934 and Rule 10b-5 as...

Continue Reading
McDermott Expands Board with New Strategic Leaders

Updated Category News Views 286

McDermott Strengthens Leadership with New Board Appointments McDermott International, Ltd has made a significant strategic move by announcing the addition of two accomplished professionals, Michael Martino and Farhad Nanji, to its Board of Directors. This change is aimed at bolstering the company’s leadership as it navigates the complex landscapes of the energy...

Continue Reading
United Therapeutics Achieves Record Stock Price of $366.23

Updated Category News Views 52

United Therapeutics Reaches New Heights in Stock Value United Therapeutics Corporation (NASDAQ: UTHR) has achieved a remarkable milestone by reaching an all-time high of $366.23. This significant increase signifies a robust period of growth for the biotech company, which has seen its stock jump by an impressive 54.22% over the past year. The surge is largely attributed to...

Continue Reading
DoorDash Surges to New Heights as Growth Strategies Flourish

Updated Category News Views 303

DoorDash Reaches New Stock Heights DoorDash (NASDAQ: DASH) has experienced a remarkable surge, with its stock recently hitting a 52-week high of $181.78. This leap signifies not only a thriving business model but also a considerable increase in investor confidence in the food delivery service. With a market cap of $75.3 billion, DoorDash has shown impressive growth with a...

Continue Reading